Syros Pharmaceuticals Overview
Syros Pharmaceuticals (SYRS) has a ROE of 821.89%, above the Healthcare sector average of 22.01%.
Get informed when a big investor buys or sells
+ Follow821.89%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, SYRS shows a ROE of 821.89%. That is above the Healthcare sector average of 22.01%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 22.01%. Syros Pharmaceuticals is at 821.89%, which is higher that average. That is roughly 3634.2% above the sector mean. Use the comparison chart on this page to see how SYRS stacks up against individual peers as well.
Check the historical chart to see whether SYRS's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Syros Pharmaceuticals with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Syros Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 821.89%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 22.01%, while SYRS is at 821.89%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
